The nominating institution Max Planck Society on the breakthrough:
Kaufmann’s work on Tuberculosis shows how basic research can lead to the rational design of novel interventions. The vaccine VPM1002 has been licensed to Vakzine Projekt-Management, Hannover / Serum Institute India, Pune. It has successfully completed phase-I clinical trials in adults and a phase-II clinical trial in neonates, demonstrating safety and immunogenicity of it in diff. age groups and regions. A phase-II clinical trial in HIV-exposed / unexposed neonates has been successfully completed.
Bio-Tech, Global Health, Diseases of Inequality